OxSight


The OxSight ‘SmartSpecs’ help sight impaired and blind people to navigate independently, avoid collisions and see in the dark.
Incorporated in June 2016
Origin: Oxford University, Neuroscience
Since 1987, Oxford University Innovation has been responsible for creating spinout companies based on academic research generated within and owned by the University of Oxford, and in recent years has spun out 15-20 new companies every year.
Over £2.5bn in external investment has been raised by Oxford University Innovation spinouts since 2010, and ten of our current portfolio are currently listed in London and New York.
The creation of new spinout companies, most of which are listed below, also channels millions of pounds back into University research, benefits local economic development and has created many new jobs in the region.
The OxSight ‘SmartSpecs’ help sight impaired and blind people to navigate independently, avoid collisions and see in the dark.
Incorporated in June 2016
Origin: Oxford University, Neuroscience
OxSonics provide economic and scalable life-changing treatments to solid tumour cancer patients.
Incorporated in January 2014
Origin: Oxford University, Institute of Biomedical Engineering
OxStem is a developer of cell programming therapies.
Incorporated in May 2016
Origin: Oxford University, Department of Chemistry
OxStem Beta will generate novel therapies to stimulate formation of new beta cells in the pancreas
(neogenesis) by targeting pathways that are normally only active during development or following
pancreatic injury.
Incorporated in December 2018
Origin: Oxford University, Department of Pathology
OxStem Immuno aims to develop small molecule drugs that augment macrophage efferocytosis in
vitro and enhance tissue repair in vivo. These therapies will supercede the need for cell transplantation
or cytokine therapy in the context of tissue repair for chronic wounds and a range of inflammatory
conditions.
Incorporated in December 2018
Origin: Oxford University, Department of Physiology, Anatomy and Genetics
Contact: Adam Workman
Developing 3D printing techniques to produce a range of tissue-like and functional tissues for medical research and clinical applications. Their vision is to ultimately produce tissues that can be used in the clinic for organ repair or replacement.
Origin: Oxford University, Department of Chemistry
Oxvalue.ai offers a useful new approach for appraising technology, and an important guide for decision-making in technology investment, transfer and commercialisation.
Incorporated in January 2023
The technology consists of two patent families which collectively enable the development of cost effective, off-the-shelf vaccines based on a proprietary dendritic cell subset for the treatment of solid tumour cancers. The technology overcomes certain key roadblocks previously associated with dendritic cell vaccine technology.
Incorporated in March 2021
Origin: Oxford University, Sir William Dunn School of Pathology
OxVent Limited is a joint-venture social enterprise that will license the OxVent ventilator design for international deployment in Covid19 and beyond, and provide consultancy on its testing, regulatory approval and manufacturing.
Incorporated in September 2020
Origin: Oxford University, Department of Engineering Science
Biopharmaceutical company treating patients with chronic infectious diseases and cancer. In 2007 Oxxon Therapeutics was acquired by Oxford BioMedica plc.
Incorporated in June 1999
Origin: Oxford University
Low cost three dimensional imaging of museum artifacts.
Incorporated in January 2018
Origin: Oxford University
Contact: Philippa Christoforou
Provides advanced insights on global information operations, data flows, and public understanding of critical issues.
Incorporated in December 2022
Origin: Oxford University, Oxford Internet Institute
Therapeutics biotech company developing proprietary drug delivery platform technology.
Incorporated in March 2018
Origin: Oxford University, Department of Physiology, Anatomy and Genetics
Developing solutions for major unmet needs in diagnostic medicine in multiple internal organs. In the first instance the focus will be on, the detection and the accurate, quantitative measurement of liver, gallbladder and pancreatic disease, including precancerous and cancerous states in these organs.
Incorporated in April 2013
Origin: Oxford University, Radcliffe Department of Medicine
Augmented reality cybersecurity assistant.
Incorporated in July 2020
Origin: Oxford University, Department of Computer Science
Contact: David Howells
Using bio-inspired hydropower systems to generate power which is then converted to electricity.
Incorporated in September 2024
Origin: Oxford University, Department of Biology